Hypertriglyceridemia-Pipeline Review, H1 2016

Hypertriglyceridemia-Pipeline Review, H1 2016

  • Products Id :- GMDHC8175IDB
  • |
  • Pages: 106
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hypertriglyceridemia-Pipeline Review, H1 2016


Global Markets Direct's, 'Hypertriglyceridemia-Pipeline Review, H1 2016', provides an overview of the Hypertriglyceridemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia

The report reviews pipeline therapeutics for Hypertriglyceridemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypertriglyceridemia therapeutics and enlists all their major and minor projects

The report assesses Hypertriglyceridemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypertriglyceridemia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypertriglyceridemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypertriglyceridemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hypertriglyceridemia Overview 9

Therapeutics Development 10

Pipeline Products for Hypertriglyceridemia-Overview 10

Hypertriglyceridemia-Therapeutics under Development by Companies 11

Hypertriglyceridemia-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Hypertriglyceridemia-Products under Development by Companies 16

Hypertriglyceridemia-Companies Involved in Therapeutics Development 17

Acasti Pharma Inc. 17

Allergan Plc 18

Alnylam Pharmaceuticals, Inc. 19

Arisaph Pharmaceuticals, Inc. 20

AstraZeneca Plc 21


Cardax Pharmaceuticals, Inc. 23

Catabasis Pharmaceuticals, Inc. 24

CymaBay Therapeutics, Inc. 25

Jeil Pharmaceutical Co., Ltd. 26

Kyorin Pharmaceutical Co., Ltd. 27

Matinas BioPharma Holdings, Inc. 28

Pharmena SA 29

Sancilio & Company, Inc. 30

Thetis Pharmaceuticals LLC 31

Zydus Cadila Healthcare Limited 32

Hypertriglyceridemia-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

AEM-28-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

AEM-2814-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ALN-AC3-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

ALN-ANG-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ARI-3037MO-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

bezafibrate ER-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

BioE-1115-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CAT-2000 Series-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

CAT-2003-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

CDX-085-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

gemcabene calcium-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

icosabutate-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

ISIS-APOCIIILRx-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

MAT-9001-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

MBX-8025-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

MN-002-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

NKPL-66-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

omega-3-carboxylic acids-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

saroglitazar-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

SC-401-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Small Molecule for Hypertriglyceridaemia-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecules for Dyslipidemia and Hypertriglyceridemia-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

TP-101-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

TRIA-662-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

volanesorsen sodium-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Hypertriglyceridemia-Dormant Projects 92

Hypertriglyceridemia-Discontinued Products 94

Hypertriglyceridemia-Product Development Milestones 95

Featured News & Press Releases 95

May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen 95

Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia 95

Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims 96

Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA 96

Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 97

May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia 98

Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 98

Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial 99

Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 99

Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 100

Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 102

Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston 102

May 06, 2014: FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia 103

Mar 31, 2014: Catabasis to Present CAT-2003 Data at the American College of Cardiology's 63rd Annual Scientific Session 103

Dec 05, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia 104

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Figures

Number of Products under Development for Hypertriglyceridemia, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 33

Number of Products by Top 10 Targets, H1 2016 34

Number of Products by Stage and Top 10 Targets, H1 2016 34

Number of Products by Top 10 Mechanism of Actions, H1 2016 36

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 36

Number of Products by Routes of Administration, H1 2016 38

Number of Products by Stage and Routes of Administration, H1 2016 38

Number of Products by Molecule Types, H1 2016 40

Number of Products by Stage and Molecule Types, H1 2016 40

List of Tables

Number of Products under Development for Hypertriglyceridemia, H1 2016 10

Number of Products under Development by Companies, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Hypertriglyceridemia-Pipeline by Acasti Pharma Inc., H1 2016 17

Hypertriglyceridemia-Pipeline by Allergan Plc, H1 2016 18

Hypertriglyceridemia-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 19

Hypertriglyceridemia-Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 20

Hypertriglyceridemia-Pipeline by AstraZeneca Plc, H1 2016 21

Hypertriglyceridemia-Pipeline by BASF SE, H1 2016 22

Hypertriglyceridemia-Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 23

Hypertriglyceridemia-Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 24

Hypertriglyceridemia-Pipeline by CymaBay Therapeutics, Inc., H1 2016 25

Hypertriglyceridemia-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 26

Hypertriglyceridemia-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 27

Hypertriglyceridemia-Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 28

Hypertriglyceridemia-Pipeline by Pharmena SA, H1 2016 29

Hypertriglyceridemia-Pipeline by Sancilio & Company, Inc., H1 2016 30

Hypertriglyceridemia-Pipeline by Thetis Pharmaceuticals LLC, H1 2016 31

Hypertriglyceridemia-Pipeline by Zydus Cadila Healthcare Limited, H1 2016 32

Assessment by Monotherapy Products, H1 2016 33

Number of Products by Stage and Target, H1 2016 35

Number of Products by Stage and Mechanism of Action, H1 2016 37

Number of Products by Stage and Route of Administration, H1 2016 39

Number of Products by Stage and Molecule Type, H1 2016 41

Hypertriglyceridemia-Dormant Projects, H1 2016 92

Hypertriglyceridemia-Dormant Projects (Contd..1), H1 2016 93

Hypertriglyceridemia-Discontinued Products, H1 2016 94

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Acasti Pharma Inc.

Allergan Plc

Alnylam Pharmaceuticals, Inc.

Arisaph Pharmaceuticals, Inc.

AstraZeneca Plc


Cardax Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Jeil Pharmaceutical Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Matinas BioPharma Holdings, Inc.

Pharmena SA

Sancilio & Company, Inc.

Thetis Pharmaceuticals LLC

Zydus Cadila Healthcare Limited

Hypertriglyceridemia Therapeutic Products under Development, Key Players in Hypertriglyceridemia Therapeutics, Hypertriglyceridemia Pipeline Overview, Hypertriglyceridemia Pipeline, Hypertriglyceridemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 147300
Site License
USD 4000 INR 294600
Corporate User License
USD 6000 INR 441900



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com